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Abstract
Skeletal muscle wasting is a major component of cachectic states found in a variety of disease settings, including
cancer. As increasing caloric intake often provides little benefit in combating muscle loss in cachectic patients, a
major research focus has been to develop strategies stimulating muscle anabolic pathways - in an attempt to fight
the catabolic pathways induced during cachexia. Two recent papers have reported the beneficial effects of
blocking the myostatin/activin signalling pathway in mouse models of cancer cachexia. We discuss the implications
of their findings both with respect to the role that this signalling pathway may play in the aetiology of cachexia
and with respect to the prospects for targeting this pathway as a therapeutic strategy in patients with cachexia.
Background
Loss of skeletal muscle mass can occur in a wide range
of disease states and has significant consequences, causing
debilitating weakness and also metabolic dysfunction - as
skeletal muscle is one of the major tissues in the body
responsible for regulating energy availability and energy
expenditure. Loss of muscle mass can result either from
primary muscle degenerative diseases, such as the mus-
cular dystrophies, or as a secondary consequence of
cachectic disease processes also affecting other tissues,
such as cancer, burns, renal failure, sepsis and congestive
heart failure (for review, see [1]). In the latter class of
conditions, muscle wasting is seen in many patients with
various distinct types of cancer. In fact, unexplained
weight loss and fatigue are often the presenting symp-
toms that bring cancer patients to the doctor’s office.
Moreover, this wasting process, or cachexia, has been
cited as a major cause of actual mortality in patients with
cancer. The aetiology of cachexia has remained largely
mysterious, although several cytokines, including tumour
necrosis factor-a, interleukin-6 and interleukin-1b,h a v e
been implicated as playing a role in mediating the wast-
ing process. One of the hallmarks of cachexia is that the
loss of lean body mass cannot be prevented or reversed
simply by increasing nutritional intake. Therefore, there
has been considerable focus on developing anabolic
strategies that directly target muscle in order to preserve
muscle mass and function. Two recent papers by Benny-
Klimek et al. [2] and Zhou et al. [3] have reported studies
that investigated the potential beneficial effects of target-
ing the myostatin/activin signalling pathway in order to
provide such an anabolic stimulus to muscle in rodent
models of cancer cachexia.
Discussion
Myostatin (MSTN) is a transforming growth factor-b
(TGF-b) family member that normally acts to limit
muscle mass (for review, see [4]). Mutations in the
Mstn gene have been shown to result in dramatic
increases in muscle mass in multiple species [5-11], and
inhibitors of MSTN signalling have been shown to
cause increases in muscle growth when administered
systemically to adult mice [12-15]. As a result, there
have been extensive efforts directed at developing
strategies and agents capable of modulating this signalling
pathway for applications in a wide range of clinical
settings. The finding that overexpression of MSTN in
mice could lead to the development of a cachexia-like
syndrome characterized by an extensive loss of fat and
muscle [16] raised two important questions about poten-
tial therapeutic applications of targeting this pathway in
patients with cachexia. First, does the inappropriate
activation of this pathway play a causative role in the
development of cachexia in humans? Second, whether or
not this signalling pathway is involved in the aetiology of
cachexia, can blocking this pathway to preserve muscle
mass thereby reduce morbidity and mortality in patients
with cachexia?
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the effect of blocking the MSTN pathway in mice bear-
ing cachexia-inducing tumours. Previous studies had
shown that MSTN signals by binding initially to activin
type II receptors [17] and that a soluble form of the
activin type IIB receptor (ActRIIB or ACVR2B), consist-
ing of its ligand binding domain fused to an immuno-
globulin Fc domain, can inhibit signalling of MSTN and
other TGF-b family secreted proteins that signal via the
ActRII receptors, such as the activins [15]. Moreover,
the soluble receptor had been shown to cause significant
muscle growth (40%-60% in just 2 weeks) when admi-
nistered systemically to adult mice [15], presumably by
acting as a ‘trap’ of the circulating ligands, binding them
in serum and, thereby, preventing binding and activation
of the cellular receptor complexes (Figure 1).
Either by inoculating mice with Chinese hamster ovary
cells expressing this soluble receptor [2] or by injecting
mice directly with the purified fusion protein [3], the
two groups showed that blocking this signalling pathway
was effective in preserving muscle mass in a wide range
of muscle groups, as well as in maintaining forelimb
grip strength in mice bearing various tumour cells
known to induce wasting. Interestingly, this protective
effect was not observed when a different pharmacologi-
cal agent was used to block this pathway, namely, the
deacetylase inhibitor, trichostatin A (TSA). Although
previous studies had shown that TSA could increase the
expression of the MSTN antagonist, follistatin [18,19],
Benny-Klimek et al. found that treatment of tumour-
bearing mice with TSA could not prevent muscle loss
even at doses capable of inducing muscle growth in
Figure 1 Inhibition of myostatin (MSTN) and activin signalling by the soluble activin type IIB receptor (ActRIB). MSTN and activin signal
to target cells by binding initially to the two activin type II receptors, ActRIIA and/or ActRIIB (also called Acvr2 and Acvr2b, respectively) and
then to the type I receptors, ALK4 and/or ALK5. The activated type I receptors phosphorylate the intracellular mediators of signalling, Smad2
and/or Smad3. Signalling through this pathway results in the inhibition of muscle differentiation and growth. The activities of MSTN and activin
are regulated normally by a number of different extracellular binding proteins, such as follistatin and FSTL-3. The soluble form of ActRIIB (ActRIIB/
Fc) can act as a ligand trap by binding MSTN and activin and preventing the ligands from binding to their true receptors.
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muscle, Zhou et al. reported that treatment with the
soluble receptor could also prevent cardiac muscle atro-
phy in tumour-bearing mice. This finding is particularly
significant, as there have been concerns that blocking
MSTN signalling for clinical applications might have
adverse effects on cardiac function. Perhaps the most
spectacular result was the finding by Zhou et al.t h a t
the soluble receptor was capable of increasing survival
of mice inoculated with colon-26 (C26) carcinoma cells
even though the intervention had no effect on actual
tumour growth. Hence, these studies have provided
exciting and compelling data that blocking muscle wast-
ing per se can have significant beneficial effects on both
morbidity and mortality in the setting of cancer and
that agents capable of blocking this signalling pathway
may be effective means of achieving this end.
What is less clear is whether these studies get us any
closer to understanding the role that this signalling
pathway may play in the aetiology of cachexia. The fact
that muscle mass is preserved by blocking this pathway
does not necessarily mean that overactivity of the path-
way is responsible for inducing wasting. Blocking MSTN
signalling with agents like the soluble receptor is known
to induce significant muscle growth, and it could be
that these anabolic effects may simply be compensating
for the muscle wasting that is being induced by activa-
tion of other pathways. In this respect, Zhou et al.
found Mstn messenger RNA (mRNA) levels in muscle
to be elevated by about two-fold in C26 tumour-bearing
mice. However, Benny-Klimek et al.s h o w e du s i n gt w o
different tumour lines (Lewis lung carcinoma and
B16F10 melanoma) that Mstn knockout mice are not
only susceptible to tumour-induced wasting but, for rea-
sons that are unclear, actually appear to exhibit an exag-
gerated response. Zhou et al. further examined the role
of this signalling pathway by focusing on the possibility
that the culprit in cancer cachexia may not be MSTN
itself but activins, which are TGF-b family members
capable of signalling through the same receptors as
MSTN (for review, see [20]). Previous studies had
shown that several TGF-b family members, including
activins, are as active as MSTN in inhibiting myoblast
differentiation, acting through the ActRIIB pathway [21],
and that electroporation of an activin A expression cas-
sette directly into muscle can induce myofiber atrophy
[22], suggesting that activin A and MSTN may be cap-
able of activating the same signalling cascade leading to
wasting. Zhou et al. present two sets of studies examin-
ing the possible role that activins may play in inducing
cancer cachexia.
In one set of studies, they utilized a genetic model of
tumourigenesis in which the normal balance of inhibin/
activin signalling had been disrupted by a targeted
mutation in the Inha gene, which encodes the inhibin-a
subunit. Inhibins and activins, which generally have
counteracting biological activities, are dimers that differ
with respect to their subunit composition, with inhibins
consisting of a and b subunits and activins consisting of
just b s u b u n i t s .H e n c e ,m i c el a c k i n gi n h i b i n - a have
excess levels of activin signalling, and previous studies
have demonstrated that these mice develop both
gonadal and adrenal tumours and exhibit a cachexia-like
syndrome characterized by severe weight loss, hepatocel-
lular necrosis and gastric mucosal atrophy [23,24]. Zhou
et al. show that these mice also develop skeletal muscle
atrophy and that this muscle wasting can be blocked by
administering the soluble activin type IIB receptor.
Although these studies demonstrate that excess activin
activity can ultimately lead to muscle loss, additional
studies are needed in order to help us to understand the
relevance of these findings to what may be happening in
cancer cachexia. In particular, it will be important to
determine the extent to which the effects on muscle
seen in this model reflect excess signalling of activin
directly to muscle versus activation of atrophy-inducing
pathways as a result of tumour development. The inter-
pretation of these studies is somewhat complicated by
the fact that the development of tumours in these mice
is itself dependent on activin signalling; that is, blocking
activin activity using a soluble form of a different activin
type II receptor had previously been shown to block not
only the cachexia-like syndr o m ei nt h e s em i c eb u ta l s o
tumour progression [25].
In a second set of studies, Zhou et al.s u r v e y e da
number of human tumours and identified several that
express high levels of activin A. They went on to show
that two of these tumour lines could induce muscle loss
when inoculated into nude mice and that this wasting
process could, again, be blocked by administering the
soluble receptor. Although these findings were consis-
tent with the model that increased activin signalling
played a causative role in inducing wasting, it will be
important to carry out additional studies to further
characterize these human tumours with respect to their
ability to induce cachexia. For example, is there is corre-
lation between expression levels of activin in the tumour
lines and their ability to induce wasting? Similarly, does
blocking activin expression in a given tumour line abro-
gate its ability to induce wasting? Furthermore, as in the
case of the tumours that developed in the inhibin-a
knockout mice, Zhou et al. reported that the soluble
receptor also suppressed the growth of the human
tumours in mice, making it difficult to attribute the
wasting process to the direct effects of activin on
muscle.
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What we are left with is the fundamental observation
that blocking the MSTN/activin signalling pathway in
the context of cancer cachexia can have significant ben-
eficial effects on both morbidity and mortality, leaving
somewhat open the question of whether activation of
this pathway may play a causative role in this process.
This issue of causality could have important implica-
tions not only for the understanding of the basic biology
of cachexia but also for pursuing this therapeutic strat-
egy to treat cachectic patients. It seems reasonable to
expect that the aetiology of cachexia may be complex
and/or heterogeneous and may result from aberrant
activity of multiple signalling pathways, particularly if
one also considers cachexia that results not only from
cancer but also from a variety of other disease processes.
Hence, it is certainly possible that the MSTN/activin
pathway may be activated in only a subset of patients
and that the extent to which a given patient’s cachexia
is responsive or refractory to this therapeutic approach
may be dependent on the extent to which the pathway
is activated in any individual case.
A causal link between skeletal muscle wasting and
activation of MSTN signalling has, perhaps, been more
convincingly established in the cachexia seen in the set-
ting of heart failure. In particular, Mstn expression has
been shown to be upregulated in the heart in animal
models of ischemic and pressure overload injury [26-28]
as well as in humans with heart failure [29]. Impor-
tantly, mice carrying a heart-specific knockout of the
Mstn gene appear to be resistant to skeletal muscle loss
following transverse aortic constriction [30]. Hence, if
this same mechanism is responsible for the development
of cardiac cachexia in humans, blocking MSTN signal-
ling in this disease context has the potential to target
the actual root cause of skeletal muscle wasting, which
has been shown to be a significant risk factor for mor-
tality in patients with heart failure [31].
On the other hand, this question of underlying mechan-
ism may be of purely academic interest if this therapeutic
approach turns out to be effective in preserving muscle
mass and reducing morbidity and mortality, regardless of
the underlying cause of the cachexia. Indeed, the studies
by Zhou et al. showing that the soluble receptor can
improve survival of mice bearing certain tumours without
directly perturbing the pathways that induce cancer or the
consequent downstream activation of atrophy-signalling
molecules secreted by the tumour provides compelling
support for the notion that maintaining muscle mass is
per se helpful in improving survival in otherwise cachectic
conditions. An important question is how generalizable
this beneficial effect on survival will turn out to be, not
only with respect to cachexia induced by other types of
cancers but also with respect to cachexia induced by other
disease states. Similarly, it will be critical to determine
whether the muscle anabolic capacity of agents like the
soluble receptor varies depending on the physiological and
disease context in which muscle loss is occurring. Given
the extensive effort that is being directed by both the aca-
demic and biotechnology/pharmaceutical research com-
munities to develop and test agents capable of blocking
the MSTN/activin signalling pathway, it seems likely that
we will have answers to at least some of these questions in
the near future.
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